24/7 Market News Snapshot 29 September, 2025 – Predictive Oncology Inc. Common Stock (NASDAQ:POAI)
DENVER, Colo., 29 September, 2025 (www.247marketnews.com) – (Nasdaq:POAI) are discussed in this article.
Predictive Oncology Inc. (Nasdaq:POAI) is experiencing significant momentum in the market, evidenced by a remarkable pre-market trading spike that saw shares jump over 258% to $2.78, following a previous close of $0.775. The surge was accompanied by a trading volume of approximately 10.95 million shares, reflecting heightened investor interest driven by the company’s innovative advancements in predictive analytics for cancer treatment.
In tandem with this market enthusiasm, Predictive Oncology is advancing its strategic expansion into the digital asset sector. The company has successfully completed two private placement transactions, generating around $344.4 million to enhance its artificial intelligence (AI) and machine learning initiatives, aimed at improving early drug discovery and drug development for cancer patients globally.
Key to this initiative is the appointment of Shawn Matthews, CEO of DNA Holdings and former CEO of Cantor Fitzgerald, to the Board of Directors. This strategic addition aims to strengthen the company’s commitment to harnessing advanced technology within healthcare solutions. The fundraising comprises a Cash PIPE, expected to yield approximately $51.7 million from the sale of around 66.7 million shares, and a Crypto PIPE involving pre-funded warrants for up to 223.6 million shares, supported by about $292.7 million in Aethir tokens.
Raymond Vennare, CEO and Chairman of Predictive Oncology, emphasized that this partnership with Aethir marks a transformative opportunity, enabling the company to construct a robust digital asset treasury strategy. With an aim to democratize access to high-performance AI infrastructure, the Aethir network is set to play a monumental role in redefining drug discovery processes, further enhancing the potential impact of AI technologies on patient outcomes in oncology.
Related news for (POAI)
- Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
- UPDATE – Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
- 24/7 Market News Snapshot 22 May, 2025 – Predictive Oncology Inc. Common Stock (NASDAQ:POAI)
- Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology